Physician profile
Lamyen Tran
NPI 1538134622
$12,546.52
in general payments reported to CMS, 2019-2025
43 companies · $1,684 in 2025
The $1,684 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,235 · 2020: $1,066 · 2021: $1,524 · 2022: $3,212 · 2023: $2,227 · 2024: $1,600 · 2025: $1,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,510.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,851.68 | 2022 | |
| Abbvie INC. | $1,309.40 | 2020-2025 | Vraylar, Ubrelvy, Linzess |
| Novo Nordisk INC | $1,031.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $960.99 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $885.97 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $628.03 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $543.51 | 2020-2025 | Jardiance, Synjardy |
| Pfizer INC. | $541.88 | 2019-2025 | |
| Amarin Pharma, INC. | $482.66 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $465.48 | 2019-2025 | Spravato |
| Abbott Laboratories | $408.94 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Eisai INC. | $403.12 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $294.52 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Currax Pharmaceuticals LLC | $290.81 | 2019-2025 | Contrave |
| Corcept Therapeutics | $236.82 | 2024-2025 | Korlym |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $230.64 | 2020-2023 | Myrbetriq, Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $194.82 | 2019-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $184.78 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $169.27 | 2023-2025 | |
| Allergan, INC. | $133.19 | 2019-2020 | |
| Amgen INC. | $127.65 | 2023-2025 | Otezla, Repatha, Repatha |
| Biohaven Pharmaceuticals, INC. | $125.79 | 2020-2021 | |
| Exact Sciences Corporation | $112.69 | 2024-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $94.53 | 2023-2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $93.06 | 2021 | |
| Dexcom, INC. | $89.65 | 2023-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.16 | 2019-2025 | Xifaxan, Trulance |
| Sanofi Pasteur INC. | $80.93 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $76.16 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $68.87 | 2023-2025 | Gemtesa |
| Edwards Lifesciences Corporation | $48.48 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Genentech USA, INC. | $36.90 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $35.46 | 2024-2025 | Rexulti |
| Bausch Health US, LLC | $28.08 | 2022 | |
| Axsome Therapeutics, INC. | $27.07 | 2025 | Symbravo |
| Avinger INC. | $24.71 | 2023 | Pantheris |
| Exeltis, USA INC. | $24.14 | 2024 | Slynd |
| Nevro Corp. | $23.11 | 2024 | Senza |
| Esperion Therapeutics, INC. | $19.88 | 2021 | |
| Impel Pharmaceuticals INC. | $19.67 | 2022 | |
| Therapeuticsmd, INC. | $18.24 | 2019 | |
| Renalytix Ai, INC. | $16.96 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Nalpropion Pharmaceuticals LLC | $16.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lamyen Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.